TVTX logo

Travere Therapeutics (TVTX) EBIT

annual EBIT:

-$309.33M+$55.45M(+15.20%)
December 31, 2024

Summary

  • As of today (July 1, 2025), TVTX annual earnings before interest & taxes is -$309.33 million, with the most recent change of +$55.45 million (+15.20%) on December 31, 2024.
  • During the last 3 years, TVTX annual EBIT has fallen by -$112.13 million (-56.86%).
  • TVTX annual EBIT is now -373.22% below its all-time high of $113.22 million, reached on December 31, 2015.

Performance

TVTX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXincome statement metrics

quarterly EBIT:

-$38.33M+$19.19M(+33.37%)
March 31, 2025

Summary

  • As of today (July 1, 2025), TVTX quarterly earnings before interest & taxes is -$38.33 million, with the most recent change of +$19.19 million (+33.37%) on March 31, 2025.
  • Over the past year, TVTX quarterly EBIT has increased by +$94.64 million (+71.17%).
  • TVTX quarterly EBIT is now -126.43% below its all-time high of $145.03 million, reached on September 30, 2015.

Performance

TVTX quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXincome statement metrics

TTM EBIT:

-$214.69M+$94.64M(+30.59%)
March 31, 2025

Summary

  • As of today (July 1, 2025), TVTX TTM earnings before interest & taxes is -$214.69 million, with the most recent change of +$94.64 million (+30.59%) on March 31, 2025.
  • Over the past year, TVTX TTM EBIT has increased by +$189.41 million (+46.87%).
  • TVTX TTM EBIT is now -270.89% below its all-time high of $125.63 million, reached on September 30, 2015.

Performance

TVTX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

TVTX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+15.2%+71.2%+46.9%
3 y3 years-56.9%+47.8%+3.5%
5 y5 years-142.4%-188.6%-131.5%

TVTX EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-56.9%+15.2%at high+71.2%at high+46.9%
5 y5-year-142.4%+15.2%-115.8%+71.2%-175.1%+46.9%
alltimeall time-373.2%+15.2%-126.4%+71.2%-270.9%+46.9%

TVTX EBIT History

DateAnnualQuarterlyTTM
Mar 2025
-
-$38.33M(-33.4%)
-$214.69M(-30.6%)
Dec 2024
-$309.33M(-15.2%)
-$57.52M(+10.5%)
-$309.33M(-8.4%)
Sep 2024
-
-$52.06M(-22.0%)
-$337.51M(-9.2%)
Jun 2024
-
-$66.78M(-49.8%)
-$371.86M(-8.0%)
Mar 2024
-
-$132.97M(+55.1%)
-$404.11M(+10.8%)
Dec 2023
-$364.78M(+13.9%)
-$85.71M(-0.8%)
-$364.77M(+0.8%)
Sep 2023
-
-$86.41M(-12.7%)
-$361.78M(+1.5%)
Jun 2023
-
-$99.02M(+5.8%)
-$356.46M(+10.9%)
Mar 2023
-
-$93.64M(+13.2%)
-$321.45M(+6.7%)
Dec 2022
-$320.14M(+62.3%)
-$82.72M(+2.0%)
-$301.21M(-0.5%)
Sep 2022
-
-$81.09M(+26.7%)
-$302.66M(+20.0%)
Jun 2022
-
-$64.01M(-12.8%)
-$252.27M(+13.4%)
Mar 2022
-
-$73.40M(-12.8%)
-$222.37M(+12.8%)
Dec 2021
-$197.20M(+16.2%)
-$84.16M(+174.2%)
-$197.20M(-14.4%)
Sep 2021
-
-$30.70M(-10.0%)
-$230.37M(+6.0%)
Jun 2021
-
-$34.11M(-29.3%)
-$217.43M(+6.2%)
Mar 2021
-
-$48.23M(-58.9%)
-$204.69M(+20.6%)
Dec 2020
-$169.74M(+33.0%)
-$117.33M(+560.7%)
-$169.74M(+117.5%)
Sep 2020
-
-$17.76M(-16.9%)
-$78.04M(-15.9%)
Jun 2020
-
-$21.37M(+60.9%)
-$92.75M(-11.8%)
Mar 2020
-
-$13.28M(-48.2%)
-$105.19M(-17.6%)
Dec 2019
-$127.62M(+38.6%)
-$25.63M(-21.1%)
-$127.62M(+22.1%)
Sep 2019
-
-$32.47M(-4.0%)
-$104.48M(-15.5%)
Jun 2019
-
-$33.81M(-5.3%)
-$123.59M(+11.5%)
Mar 2019
-
-$35.71M(+1332.5%)
-$110.88M(+20.3%)
Dec 2018
-$92.06M(+70.7%)
-$2.49M(-95.2%)
-$92.16M(-7.5%)
Sep 2018
-
-$51.57M(+144.3%)
-$99.60M(+50.0%)
Jun 2018
-
-$21.11M(+24.2%)
-$66.39M(+11.1%)
Mar 2018
-
-$16.99M(+71.1%)
-$59.78M(+7.1%)
Dec 2017
-$53.94M
-$9.93M(-45.9%)
-$55.81M(+3.3%)
Sep 2017
-
-$18.36M(+26.6%)
-$54.04M(-18.2%)
DateAnnualQuarterlyTTM
Jun 2017
-
-$14.50M(+11.3%)
-$66.03M(-8.5%)
Mar 2017
-
-$13.02M(+59.5%)
-$72.18M(+36.6%)
Dec 2016
-$52.85M(-146.7%)
-$8.16M(-73.1%)
-$52.85M(-7.8%)
Sep 2016
-
-$30.35M(+47.0%)
-$57.35M(-148.6%)
Jun 2016
-
-$20.65M(-427.3%)
$118.03M(+1.7%)
Mar 2016
-
$6.31M(-149.8%)
$116.09M(+2.5%)
Dec 2015
$113.22M(-241.9%)
-$12.66M(-108.7%)
$113.22M(-9.9%)
Sep 2015
-
$145.03M(-742.0%)
$125.63M(-461.5%)
Jun 2015
-
-$22.59M(-758.2%)
-$34.75M(+4829.6%)
Mar 2015
-
$3.43M(-1500.8%)
-$705.00K(-97.3%)
Dec 2014
-$79.81M(+222.2%)
-$245.00K(-98.4%)
-$26.20M(-12.9%)
Sep 2014
-
-$15.35M(-234.0%)
-$30.08M(+51.3%)
Jun 2014
-
$11.46M(-151.9%)
-$19.88M(-45.4%)
Mar 2014
-
-$22.06M(+434.8%)
-$36.44M(+124.0%)
Dec 2013
-$24.77M(-18.1%)
-$4.13M(-20.0%)
-$16.27M(+33.9%)
Sep 2013
-
-$5.15M(+1.1%)
-$12.14M(+73.7%)
Jun 2013
-
-$5.10M(+170.5%)
-$6.99M(+269.0%)
Mar 2013
-
-$1.89M(>+9900.0%)
-$1.89M(>+9900.0%)
Dec 2012
-$30.26M(>+9900.0%)
-
-
Nov 2012
-
-$3200.00(+6.7%)
-$13.00K(+1.6%)
Aug 2012
-
-$3000.00(0.0%)
-$12.80K(0.0%)
May 2012
-
-$3000.00(-21.1%)
-$12.80K(0.0%)
Feb 2012
-
-$3800.00(+26.7%)
-$12.80K(+1.6%)
Feb 2012
-$12.80K(+0.8%)
-
-
Nov 2011
-
-$3000.00(0.0%)
-$12.60K(-0.8%)
Aug 2011
-
-$3000.00(0.0%)
-$12.70K(-22.1%)
May 2011
-
-$3000.00(-16.7%)
-$16.30K(-18.1%)
Feb 2011
-$12.70K
-$3600.00(+16.1%)
-$19.90K(+22.1%)
Nov 2010
-
-$3100.00(-53.0%)
-$16.30K(+23.5%)
Aug 2010
-
-$6600.00(0.0%)
-$13.20K(+100.0%)
May 2010
-
-$6600.00
-$6600.00

FAQ

  • What is Travere Therapeutics annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Travere Therapeutics?
  • What is Travere Therapeutics annual EBIT year-on-year change?
  • What is Travere Therapeutics quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Travere Therapeutics?
  • What is Travere Therapeutics quarterly EBIT year-on-year change?
  • What is Travere Therapeutics TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Travere Therapeutics?
  • What is Travere Therapeutics TTM EBIT year-on-year change?

What is Travere Therapeutics annual earnings before interest & taxes?

The current annual EBIT of TVTX is -$309.33M

What is the all time high annual EBIT for Travere Therapeutics?

Travere Therapeutics all-time high annual earnings before interest & taxes is $113.22M

What is Travere Therapeutics annual EBIT year-on-year change?

Over the past year, TVTX annual earnings before interest & taxes has changed by +$55.45M (+15.20%)

What is Travere Therapeutics quarterly earnings before interest & taxes?

The current quarterly EBIT of TVTX is -$38.33M

What is the all time high quarterly EBIT for Travere Therapeutics?

Travere Therapeutics all-time high quarterly earnings before interest & taxes is $145.03M

What is Travere Therapeutics quarterly EBIT year-on-year change?

Over the past year, TVTX quarterly earnings before interest & taxes has changed by +$94.64M (+71.17%)

What is Travere Therapeutics TTM earnings before interest & taxes?

The current TTM EBIT of TVTX is -$214.69M

What is the all time high TTM EBIT for Travere Therapeutics?

Travere Therapeutics all-time high TTM earnings before interest & taxes is $125.63M

What is Travere Therapeutics TTM EBIT year-on-year change?

Over the past year, TVTX TTM earnings before interest & taxes has changed by +$189.41M (+46.87%)
On this page